Promoter collection, Human CX3CL1 promoter
Alternative name | U2710(2088)-8 |
---|---|
Clone info. | PCR amplified human CX3CL1 promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 57371363 to 57372598(NC_000016.10); relatively -1127 to +109, where +1 corresponds to 1 nt of NM_002996.6. |
Comment | PCR cloning, forward primer: TGGAGACACCAGTACAGCTCA; reverse primer: GAGCAGCCACGACAGAGATA. Entire sequence of promoter region has not been confirmed. |
Vector backbone | pGL4.10 [Luc2] (Plasmid) |
Selectable markers | Amp^r |
Gene/insert name | Human chemokine (C-X3-C motif) ligand 1 genomic DNA |
Depositor|Developer | DNA Bank, | |
Remarks, protocol and/or map (pdf) | RDB07340.pdf |
---|
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation. |
必要書類 | 提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 謝辞の表明を必要とする。 MTAに書く付加的使用条件: 本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。 |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB07340 | pGL4-phCX3CL1 | DNA solution |
Materials & Methods section:
The pGL4-phCX3CL1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07340). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB07340_A4Df.pdf |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: pGL4-4174F Sequence file: RDB07340_A4Dfa.seq |
---|
>07340_07340_A4Df_1_pGL4-4174F_C02_08.ab1 1 GATGGGGCAG AACATTTCTC TGGCCTAACT GGCCGGTACC TGAGCTCGCT AGCCTCGAGG 61 ATTGGAGACA CCAGTACAGC TCAGTCCTAT ACCAAGGCAG AGCTGCTGAC TCTTCTGGAG 121 TCTCAGGGAT TGTTGCCACT GCCTTTAGGG AAGGCTGCCA TGAAGGCAGA CTGTGTTCTA 181 ATGTGCTCCC AAGGCTGGCA AGCCTCTGCA CCCTTCGGTG AGAGCCTGTT GGAGGGCCGG 241 TGCTGGGAAG CCCTCTCCCC ATTGCACTAG CCCAATGCTC TCTTTGGGCA GATAGAGAAC 301 TCAGGCCCCA CGAGAGGCAA GCCTTATCCA AGCCACGGCT ACAGAGTTGA GGAGCCAAGA 361 GCCACAGAGT TATCGGGGAT GGGTTGGCAG CCACCTTGTT CTTTGGGCTA ACAGGGGCCA 421 GAGCAGAGGT GGGAGTGGGT GCAAAGCAGG GAGCGGGAGA CCGGGAGGTG GAGGCAGGGA 481 GGCCAGGGCT CTCTCCTGGG TCCTGAGCTG TCCACATTCT GCTCATCATG GTGGTGGGAG 541 GGGAGTTCTC CACTCTGATG CTGTGGATAA CCTGGGGTGG CTCCGGGCCT CAGTTTCCCC 601 ATCTATCCAT ATGAAGTTGG ACTCAATCCT TCTTTCAGCA GACCCTGCAC CAAGCCCCTG 661 CTGACTTCAG GCTCCCTGCT GGGCTCTGGA GATGCATAGA TCAACAAGGT CCCCCAGGAG 721 CTTGGGATTC TAAGAGGGGA AATTTAGGGG TCCATCCTGA TGTGGGCGAG GCATTCTCTG 781 GATCAAAGAA GAGCTTGTCA GACCCAGGAT GGAGGGGCCC TGAGTCTCTC CCGGCCCCTT 841 GGCGCCCCGC TCTCTATTCC ACGGCCTGCT GGCCTTTTGT GTGTTGCCCA CTTAGGATCA 901 AGGGCCCCAG GCCAGATCCT AGGGCATGTT CCCAGCTTGT GGCAGGAGAG GAGGCCTTTG 961 TACCCAGGCA GGCCCAGTCC AGCCTCCCGG GGAACGTCCC AGTATGACAA GCCTAGGATG 1021 GTGAGAAGCC CAGGGACACA AAGCCCGGCT TGGATCCTTG GCAACATCCC TGAGGAATCC 1081 AGCCGGCCTG CACACTGGCT CCATCTCTTC CCTTCACCTC CTGGCTGCTG AGCCTGAGCC 1141 GAGGGCAGGC CGAACCCCAT TATTA // |
Primer: pGL4-136R Sequence file: RDB07340_A4Dfb.seq |
>07340_07340_A4Df_1_pGL4-136R_D02_11.ab1 1 GTTTTTAATG GTTTTGGGCA TCTTCCATGG TGGCTTTACC AACAGTACCG GATTGCCAAG 61 CTTGGCCGCC GAGGCCAGAT CTTGATGAGC AGCCACGACA GAGATATCGG AGCCATGGCT 121 GAGGGTGGGC AAGAGTCCCG GCGGGGGCCA GGCAGGCGGC TAGAGCCAGG CGGCAGAGCT 181 CAGTGCTGTC CCCTTGCCGC CGCCAGAGAT CTGTGGCTTT TTATAATGGG GTTGGCTGCC 241 TCCGCCTCCA GCCCCCGCAG GCAGGAGGGT GGGAGGGGAG AGGAAGGGAG CCAGTGTGCA 301 GCCGCTGGAT TCCTCAGGAT GTTGCCAAGG AACCAAGCCG GCTTTGTGTC CCTGGGCTTC 361 TCACCATCCT AGGCTTGTCA TACTGGGACC TTCCCCGGGA GGCTGGACTG GGCCTGCCTG 421 GGTACAAAGG CCTCCTCTCC TGCCACAAGC TGGGAACATG CCCTAGGATC TGGCCTGGGG 481 CCCTTGATCC TAAGTGGGCA ACACACAAAA GGCCAGCAGG CCGTGGAATA GAGAGCGGGG 541 CGCCAAGGGG CCGGGAGAGA CTCAGGGCCC CTCCATCCTG GGTCTGACAA GCTCTTCTTT 601 GATCCAGAGA ATGCCTCGCC CACATCAGGA TGGACCCCTA AATTTCCCCT CTTAGAATCC 661 CAAGCTCCTG GGGGACCTTG TTGATCTATG CATCTCCAGA GCCCAGCAGG GAGCCTGAAG 721 TCAGCAGGGG CTTGGTGCAG GGTCTGCTGA AAGAAGGATT GAGTCCAACT TCATATGGAT 781 AGATGGGGAA ACTGAGGCCC GGAGCCACCC CAGGTTATCC ACAGCATCAG AGTGGAGAAC 841 TCCCCTCCCA CCACCATGAT GAGCAGAATG TGGACAGCTC AGGACCCAGG AGAGAGCCCT 901 GGCCTCCCTG CCTCCACCTC CCGGTCTCCC GCTCCCTGCT TTGCACCCAC TCCCACCTCT 961 GCTCTGGCCC CTGTTAGCCC AAAGAACAAG GTGGCTGCCA ACCCATCCCC GATACTCTGT 1021 GGCTCTTGCT CCTCAACTCT GTAGCCGTGG CTTGGATAAG CTTGCCTCTC GTGGGGCCCT 1081 GAGTTCTCTA TCTGCCCAAG AGAGCATGGG GCTAGTGCAA TGGGAGAGGC ATCCCAGCAC 1141 CGGCTCCTCC TAACCGAGCC TCTCTCCACC CGGAAA // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content